Lim Yu Jin, Koh Jaemoon, Kim Sehui, Jeon Sang-Rok, Chie Eui Kyu, Kim Kyubo, Kang Gyeong Hoon, Han Sae-Won, Kim Tae-You, Jeong Seung-Yong, Park Kyu Joo, Wu Hong-Gyun
Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea; Department of Radiation Oncology, Kyung Hee University Medical Center, Kyung Hee University School of Medicine, Seoul, Korea.
Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.
Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1216-1224. doi: 10.1016/j.ijrobp.2017.07.004.
To evaluate chemoradiotherapy (CRT)-induced changes in the expression levels of programmed death-ligand 1 (PD-L1) and CD8 tumor-infiltrating lymphocytes (TILs) and prognostic associations in rectal cancer.
We performed a paired analysis using pre-CRT biopsies and the corresponding post-CRT resected tissues of 123 rectal cancer patients undergoing preoperative CRT followed by surgery between 2005 and 2012. Immunohistochemistry of PD-L1 and CD8 was analyzed for the specimens.
The expression levels of PD-L1 and density of CD8 TILs increased after CRT (P<.001 for both). With cutoffs using each median value, sustained higher expression of PD-L1 at pre- and post-CRT (high-to-high) was associated with less increase in the density of CD8 TILs (P=.020). Patients representing sustained high-to-high PD-L1 expression had poorer overall survival and disease-free interval on univariate Kaplan-Meier analysis (P=.018 and .029, respectively), with inferior disease-free interval in low-to-low density CD8 TILs (P=.010). On multivariate analysis, 2 subgroups with high baseline PD-L1 expression level, the high-to-low and high-to-high alterations, showed worse overall survival (hazard ratio 8.34, 95% confidence interval 1.85-37.53 and hazard ratio 11.03, 95% confidence interval 2.33-52.29, respectively), with the highest mortality risk observed in the high-to-high group.
This study verified the CRT-induced immunologic shift toward increases in PD-L1 expression and density of CD8 TILs in rectal cancer patients. The alteration profiles of checkpoint-related molecules identified the patients with poor prognosis, suggesting potential candidates who can benefit from combining CRT and checkpoint inhibitors.
评估放化疗(CRT)诱导的程序性死亡配体1(PD-L1)和CD8肿瘤浸润淋巴细胞(TILs)表达水平的变化及其与直肠癌预后的相关性。
我们对2005年至2012年间123例接受术前CRT然后手术的直肠癌患者的CRT前活检组织和相应的CRT后切除组织进行了配对分析。对标本进行PD-L1和CD8免疫组织化学分析。
CRT后PD-L1表达水平和CD8 TILs密度增加(两者P均<0.001)。以每个中位数为临界值时,CRT前后PD-L1持续高表达(高到高)与CD8 TILs密度增加较少相关(P = 0.020)。在单因素Kaplan-Meier分析中,持续高到高PD-L1表达的患者总生存期和无病间期较差(分别为P = 0.018和0.029),低密度到低密度CD8 TILs患者的无病间期较差(P = 0.010)。多因素分析显示,2个基线PD-L1表达水平高的亚组,即高到低和高到高改变,总生存期较差(风险比分别为8.34,95%置信区间1.85 - 37.53和风险比11.03,95%置信区间2.33 - 52.29),高到高组观察到的死亡风险最高。
本研究证实了CRT诱导直肠癌患者免疫向PD-L1表达增加和CD8 TILs密度增加的转变。检查点相关分子的改变谱确定了预后不良的患者群体,提示可能从CRT与检查点抑制剂联合治疗中获益的潜在患者。